[go: up one dir, main page]

RU2319701C2 - ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I - Google Patents

ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I Download PDF

Info

Publication number
RU2319701C2
RU2319701C2 RU2003128535/04A RU2003128535A RU2319701C2 RU 2319701 C2 RU2319701 C2 RU 2319701C2 RU 2003128535/04 A RU2003128535/04 A RU 2003128535/04A RU 2003128535 A RU2003128535 A RU 2003128535A RU 2319701 C2 RU2319701 C2 RU 2319701C2
Authority
RU
Russia
Prior art keywords
mglur
group
metabotropic glutamate
glutamate receptors
antagonistic activity
Prior art date
Application number
RU2003128535/04A
Other languages
English (en)
Other versions
RU2003128535A (ru
Inventor
ВАГЕНЕН Брадфор ВАН (US)
ВАГЕНЕН Брадфор ВАН
Метвин Бенджамин ИСААК (CA)
Метвин Бенджамин ИСААК
Дональд Э. МАКЛЕД (US)
Дональд Э. МАКЛЕД
Скотт Т. МО (US)
Скотт Т. Мо
Абдельмалик СЛАССИ (CA)
Абдельмалик Сласси
Дэрил Л. СМИТ (US)
Дэрил Л. СМИТ
Томас М. СТОРМЭН (US)
Томас М. СТОРМЭН
Сузан М. ШИХЭН (US)
Сузан М. ШИХЭН
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23028892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2319701(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2003128535A publication Critical patent/RU2003128535A/ru
Application granted granted Critical
Publication of RU2319701C2 publication Critical patent/RU2319701C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к области медицинской химии и касается соединений и фармацевтических композиций, которые действуют в качестве антагонистов метаботропных глютаматных рецепторов. 3 н. и 4 з.п. ф-лы, 3 табл.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171
Figure 00000172
Figure 00000173
Figure 00000174
Figure 00000175
Figure 00000176
Figure 00000177
Figure 00000178
Figure 00000179
Figure 00000180
Figure 00000181
Figure 00000182
Figure 00000183
Figure 00000184
Figure 00000185
Figure 00000186
Figure 00000187
Figure 00000188
Figure 00000189
Figure 00000190
Figure 00000191
Figure 00000192
Figure 00000193
Figure 00000194
Figure 00000195
Figure 00000196
Figure 00000197
Figure 00000198
Figure 00000199
Figure 00000200
Figure 00000201
Figure 00000202
Figure 00000203
Figure 00000204
Figure 00000205
Figure 00000206
Figure 00000207
Figure 00000208
Figure 00000209
Figure 00000210
Figure 00000211
Figure 00000212
Figure 00000213
Figure 00000214
Figure 00000215
Figure 00000216
Figure 00000217
Figure 00000218
Figure 00000219
Figure 00000220
Figure 00000221
Figure 00000222
Figure 00000223
Figure 00000224
Figure 00000225
Figure 00000226
Figure 00000227
Figure 00000228
Figure 00000229
Figure 00000230
Figure 00000231
Figure 00000232
Figure 00000233
Figure 00000234
Figure 00000235
Figure 00000236
Figure 00000237
Figure 00000238
Figure 00000239
Figure 00000240
Figure 00000241
Figure 00000242
Figure 00000243
Figure 00000244
Figure 00000245
Figure 00000246
Figure 00000247
Figure 00000248
Figure 00000249
Figure 00000250
Figure 00000251
Figure 00000252
Figure 00000253
Figure 00000254
Figure 00000255
Figure 00000256
Figure 00000257
Figure 00000258
Figure 00000259
Figure 00000260
Figure 00000261
Figure 00000262
Figure 00000263
Figure 00000264
Figure 00000265
Figure 00000266
Figure 00000267
Figure 00000268
Figure 00000269
Figure 00000270
Figure 00000271
Figure 00000272
Figure 00000273
Figure 00000274
Figure 00000275
Figure 00000276
Figure 00000277
Figure 00000278
Figure 00000279
Figure 00000280
Figure 00000281
Figure 00000282
Figure 00000283
Figure 00000284
Figure 00000285
Figure 00000286
Figure 00000287
Figure 00000288
Figure 00000289
Figure 00000290
Figure 00000291
Figure 00000292
Figure 00000293
Figure 00000294
Figure 00000295
Figure 00000296
Figure 00000297
Figure 00000298
Figure 00000299
Figure 00000300

Claims (7)

1. Гетерополициклическое соединение, выбранное из группы, состоящей из следующих соединений:
Figure 00000301
Figure 00000302
Figure 00000303
Figure 00000304
Figure 00000305
Figure 00000306
Figure 00000307
Figure 00000308
Figure 00000310
Figure 00000311
Figure 00000312
Figure 00000313
Figure 00000314
Figure 00000315
Figure 00000316
Figure 00000317
Figure 00000318
Figure 00000319
Figure 00000320
Figure 00000321
Figure 00000322
Figure 00000323
Figure 00000324
Figure 00000325
Figure 00000326
Figure 00000327
Figure 00000328
Figure 00000329
Figure 00000330
Figure 00000331
Figure 00000332
Figure 00000333
Figure 00000334
Figure 00000335
Figure 00000336
Figure 00000337
Figure 00000338
Figure 00000339
Figure 00000340
Figure 00000341
Figure 00000342
Figure 00000343
Figure 00000344
Figure 00000345
Figure 00000346
Figure 00000347
Figure 00000348
Figure 00000349
Figure 00000350
Figure 00000351
Figure 00000352
Figure 00000353
Figure 00000354
Figure 00000355
Figure 00000356
Figure 00000357
Figure 00000358
Figure 00000359
Figure 00000360
Figure 00000361
Figure 00000362
Figure 00000363
Figure 00000364
Figure 00000365
Figure 00000366
Figure 00000367
Figure 00000368
Figure 00000369
Figure 00000370
Figure 00000371
Figure 00000372
Figure 00000373
Figure 00000374
Figure 00000375
Figure 00000376
Figure 00000378
Figure 00000379
Figure 00000380
Figure 00000381
Figure 00000382
Figure 00000383
Figure 00000384
Figure 00000385
Figure 00000386
Figure 00000387
Figure 00000388
Figure 00000389
Figure 00000390
Figure 00000391
Figure 00000392
Figure 00000393
Figure 00000394
Figure 00000395
Figure 00000396
или его фармацевтически приемлемая соль.
2. Соединение по п.1, отличающееся тем, что оно представляет собой 3-(5-циано-2-пиридил)-5-(3-бромфенил)-1,2,4-оксадиазол.
3. Соединение по п.1, отличающееся тем, что оно представляет собой 3-(5-циано-2-пиридил)-5-(3-циано-5-фторфенил)-1,2,4-оксадиазол.
4. Соединение по п.1, отличающееся тем, что оно представляет собой 3-(5-фторпирид-2-ил)-5-(3-циано-5-хлорфенил)-1,2,4-оксадиазол.
5. Фармацевтическая композиция, обладающая антагонистической активностью в отношении метаботропных глютаматных рецепторов mGluR группы I, отличающаяся тем, что она содержит терапевтически эффективное, нетоксичное количество соединения по п.1 и фармацевтически приемлемый носитель.
6. Применение соединения по пп.1-4 для получения композиции, обладающей антагонистической активностью в отношении метаботропных глютаматных рецепторов mGluR группы I.
7. Применение по п.6, при котором композиция обладает антагонистической активностью в отношении метаботропных глютаматных рецепторов mGluR5.
RU2003128535/04A 2001-02-21 2002-02-19 ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I RU2319701C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26984701P 2001-02-21 2001-02-21
US60/269,847 2001-02-21

Publications (2)

Publication Number Publication Date
RU2003128535A RU2003128535A (ru) 2005-04-10
RU2319701C2 true RU2319701C2 (ru) 2008-03-20

Family

ID=23028892

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003128535/04A RU2319701C2 (ru) 2001-02-21 2002-02-19 ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I

Country Status (24)

Country Link
EP (2) EP1379525B1 (ru)
JP (2) JP4519404B2 (ru)
KR (1) KR100838447B1 (ru)
CN (2) CN1853630A (ru)
AT (1) ATE375340T1 (ru)
AU (1) AU2002306517B2 (ru)
BR (1) BR0207390A (ru)
CA (1) CA2438991C (ru)
CY (1) CY1107005T1 (ru)
DE (1) DE60222872T2 (ru)
DK (1) DK1379525T3 (ru)
ES (1) ES2292830T3 (ru)
IL (1) IL157491A0 (ru)
IS (1) IS2564B (ru)
MX (1) MXPA03007513A (ru)
NO (1) NO326105B1 (ru)
NZ (1) NZ527691A (ru)
PL (1) PL369598A1 (ru)
PT (1) PT1379525E (ru)
RU (1) RU2319701C2 (ru)
SI (1) SI1379525T1 (ru)
UA (1) UA74419C2 (ru)
WO (1) WO2002068417A2 (ru)
ZA (1) ZA200306493B (ru)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458385A4 (en) * 2001-12-19 2005-12-21 Merck & Co Inc HETEROARYLE SUBSTITUTED IMIDAZOLES MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR TYPE 5
AU2002349754B2 (en) * 2002-01-28 2008-01-31 Fuji Yakuhin Co., Ltd. Novel 1,2,4-triazole compound
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
US7144876B2 (en) * 2002-12-18 2006-12-05 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CN1788008A (zh) * 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
US20060166972A1 (en) * 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
CN1906187A (zh) * 2003-12-19 2007-01-31 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5配体的5－氟－,氯－和氰基－吡啶－2－基－四唑类化合物
NZ547965A (en) * 2003-12-24 2009-12-24 Prosidion Ltd 1,2,4-Oxadiazole derivatives as GPCR receptor agonists
CA2570318A1 (en) * 2004-06-30 2006-01-12 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
AU2005295727A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
EP1848430B1 (en) 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006074884A1 (en) 2005-01-14 2006-07-20 F.Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mglur5 antagonists
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
CN101203220A (zh) * 2005-06-28 2008-06-18 阿斯利康(瑞典)有限公司 新用途
KR101370280B1 (ko) 2005-07-26 2014-03-06 바이알 - 포르텔라 앤드 씨에이 에스에이 Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
US7858649B2 (en) 2005-10-14 2010-12-28 Neurosearch A/S Imidazole derivatives and their use for modulating the GABAA receptor complex
BRPI0618636A2 (pt) 2005-11-08 2011-09-06 Hoffmann La Roche derivados de tiazolo [4,5-c]piridina
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
MX2009002233A (es) 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
SI2069335T1 (sl) 2006-09-08 2013-04-30 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kot imunomodulacijska sredstva
CN101522645B (zh) 2006-09-21 2013-01-09 埃科特莱茵药品有限公司 苯衍生物及其免疫调节剂的用途
MX2009003892A (es) * 2006-10-25 2009-04-23 Neurosearch As Compuestos de oxadiazol y tiadiazol y su uso como moduladores del receptor de acetilcolina nicotinico.
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
MX2009006304A (es) 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
HUE031317T2 (hu) 2007-01-31 2017-07-28 Bial - Portela & Ca S A Specifikus dózisprotokollal adagolt COMT inhibitor nitrokatechin származékok
US9085566B2 (en) 2007-02-02 2015-07-21 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and related disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
EP2120580B1 (en) * 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
BRPI0808789A2 (pt) 2007-03-16 2014-08-12 Actelion Pharmaceuticals Ltd Compostos e composição farmacêutica de derivados aminopiridina e uso destes
US8012986B2 (en) * 2007-04-02 2011-09-06 Hoffmann-La Roche Inc. Pyridine and pyrimidine derivatives as MGLUR2 antagonists
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
BRPI0815190A2 (pt) 2007-08-17 2015-03-31 Actelion Pharmaceuticals Ltd Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
JP5718053B2 (ja) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド 治療用イソオキサゾール化合物
EP2215086B1 (en) 2007-11-20 2011-08-24 Sumitomo Chemical Company, Limited Pyridine compound, pesticidal composition and method of controlling pest
WO2009071690A2 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
WO2009071689A2 (de) 2007-12-07 2009-06-11 Abbott Gmbh & Co. Kg 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EA018891B1 (ru) 2008-10-23 2013-11-29 Вертекс Фармасьютикалз, Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
KR102023255B1 (ko) 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
US9040568B2 (en) 2009-05-29 2015-05-26 Abbvie Inc. Pharmaceutical compositions for the treatment of pain
AR077413A1 (es) 2009-07-16 2011-08-24 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo
US8314250B2 (en) 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
MX350009B (es) 2011-01-19 2017-08-23 Idorsia Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo.
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
CN104144925A (zh) * 2011-10-17 2014-11-12 拜耳知识产权有限责任公司 作为hif抑制剂的取代的噁二唑基吡啶酮和噁二唑基哒嗪酮
PL2791134T3 (pl) 2011-12-13 2020-03-31 BIAL - PORTELA & Cª S.A. Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy
EP2853532B1 (en) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
AU2015274781C1 (en) 2014-06-10 2019-08-08 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
PH12017502097B1 (en) 2015-05-20 2023-05-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
LT3303330T (lt) 2015-06-03 2019-08-12 Bristol-Myers Squibb Company 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HRP20211864T1 (hr) 2015-07-06 2022-03-04 Alkermes, Inc. Inhibitori hetero-halo histonske deacetilaze
CN105541753B (zh) * 2015-12-17 2018-02-27 浙江工业大学 一种含有噻唑环的羧酰胺衍生物及其制备与应用
CN105503716A (zh) * 2016-01-30 2016-04-20 天长市淳峰精细材料合成厂 一种2,6-二氰基吡啶的制备方法
US11344539B2 (en) 2016-02-19 2022-05-31 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
AU2016400019A1 (en) 2016-03-30 2018-10-04 Sinntaxis AB Negative allosteric modulators of mGluR5 for use in the treatment of mature brain damages.
JP6946412B2 (ja) 2016-07-18 2021-10-06 ヤンセン ファーマシューティカ エヌ．ベー． タウｐｅｔ画像化リガンド
EP3392242B1 (en) * 2016-07-20 2021-02-24 LG Chem, Ltd. Novel heterocyclic compound and organic light-emitting device using same
DK3512833T3 (da) 2016-09-15 2020-10-12 Boehringer Ingelheim Int Heteroarylcarboxamidforbindelser som inhibitorer af ripk2
MX394242B (es) 2017-01-11 2025-03-24 Rodin Therapeutics Inc Inhibidores biciclicos de histona desacetilasa
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
KR20190070586A (ko) 2017-12-13 2019-06-21 엘지디스플레이 주식회사 전자수송 재료용 화합물 및 이를 포함하는 유기 발광 다이오드
SG11202008739TA (en) * 2018-04-12 2020-10-29 Bayer Ag N-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-1h-1,2,4-triazol-5-yl]ethyl}benzamide derivatives and the corresponding pyridine-carboxamide derivatives as pesticides
CN113620829B (zh) * 2020-05-07 2024-05-31 鲁南制药集团股份有限公司 一种非布司他中间体化合物
EP4402140A1 (en) * 2021-09-14 2024-07-24 Vanderbilt University Heteroaryl-linked analogs as mglu5 negative allosteric modulators and methods of making and using the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
RU2162848C2 (ru) * 1996-02-22 2001-02-10 Пфайзер Рисерч Энд Дивелопмент Компани, Н.В./С.А. Производные окса- или тиадиазола, способ их получения (варианты), фармацевтическая композиция

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
AU780191B2 (en) * 1999-08-19 2005-03-03 Astrazeneca Ab Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
RU2162848C2 (ru) * 1996-02-22 2001-02-10 Пфайзер Рисерч Энд Дивелопмент Компани, Н.В./С.А. Производные окса- или тиадиазола, способ их получения (варианты), фармацевтическая композиция

Also Published As

Publication number Publication date
DK1379525T3 (da) 2007-12-27
ATE375340T1 (de) 2007-10-15
JP4519404B2 (ja) 2010-08-04
AU2002306517B2 (en) 2007-08-30
NO326105B1 (no) 2008-09-22
EP1379525B1 (en) 2007-10-10
IL157491A0 (en) 2004-03-28
DE60222872T2 (de) 2008-07-24
KR100838447B1 (ko) 2008-06-16
WO2002068417A3 (en) 2002-11-14
CN1853630A (zh) 2006-11-01
EP1679313A2 (en) 2006-07-12
DE60222872D1 (de) 2007-11-22
CN1649865A (zh) 2005-08-03
BR0207390A (pt) 2004-10-13
JP2004536037A (ja) 2004-12-02
IS6922A (is) 2003-08-20
EP1679313A3 (en) 2006-08-16
CN1332959C (zh) 2007-08-22
NO20033711D0 (no) 2003-08-20
NZ527691A (en) 2007-01-26
CY1107005T1 (el) 2012-09-26
MXPA03007513A (es) 2004-07-30
KR20030088434A (ko) 2003-11-19
CA2438991A1 (en) 2002-09-06
NO20033711L (no) 2003-10-17
CA2438991C (en) 2010-08-17
JP2006182789A (ja) 2006-07-13
WO2002068417A2 (en) 2002-09-06
PL369598A1 (en) 2005-05-02
ES2292830T3 (es) 2008-03-16
PT1379525E (pt) 2007-12-04
SI1379525T1 (sl) 2007-12-31
IS2564B (is) 2009-12-15
UA74419C2 (ru) 2005-12-15
ZA200306493B (en) 2004-11-22
EP1379525A2 (en) 2004-01-14
HK1060559A1 (en) 2004-08-13
RU2003128535A (ru) 2005-04-10

Similar Documents

Publication Publication Date Title
RU2319701C2 (ru) ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
RU2370495C2 (ru) Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора
SE0302760D0 (sv) New compounds
RU2412935C2 (ru) Феноксиуксусные кислоты в качестве активаторов дельта рецепторов ppar
FR2838439B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
CA2522220A1 (en) Cgrp receptor antagonists
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
ATE461196T1 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
RU2006105764A (ru) Фунгицидная тройная комбинация биологически активных веществ
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2004048345A3 (en) 2,5-diketopiperazines for the treatment of obesity
MA28393B1 (fr) Dérivés de triazole servant d'antagonistes de la vasopressine
WO2001096330A3 (en) Thrombin receptor antagonists
WO2004091514A3 (en) Cgrp receptor antagonists
JP2002523475A5 (ru)
EP2179987A3 (en) Use of heterocyclic carbaldehyde derivatives against sickle cell anemia
JP2001526218A5 (ru)
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
JP2005513006A5 (ru)
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
DE602005010401D1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
WO2006041830A3 (en) Cgrp receptor antagonists
AR060913A1 (es) Combinaciones de principios activos fungicidas
RU2318814C2 (ru) Имидазолинилметиларалкилсульфонамиды
EP0902018A3 (en) 2-(Arylphenyl)amino-imidazoline derivatives

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 8-2008

MM4A The patent is invalid due to non-payment of fees

Effective date: 20110220